An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Desoximetasone (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 26 Jan 2018 Status changed from recruiting to completed.
- 16 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2018.
- 16 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2018.